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Abstract: The present paper aims at a systematic review of the current knowledge on 
phosphatidylethanol (PEth) in blood as a direct marker of chronic alcohol use and abuse.  
In March 2012, the search through “MeSH” and “free-text” protocols in the databases 
Medline/PubMed, SCOPUS, Web of Science, and Ovid/Embase, combining the terms 
phosphatidylethanol and alcohol, provided 444 records, 58 of which fulfilled the inclusion 
criteria and were used to summarize the current evidence on the formation, distribution and 
degradation of PEth in human blood: (1), the presence and distribution of different PEth 
molecular species (2), the most diffused analytical methods devoted to PEth identification 
and quantization (3), the clinical efficiency of total PEth quantification as a marker of 
chronic excessive drinking (4), and the potential utility of this marker for identifying binge 
drinking behaviors (5). Twelve papers were included in the meta-analysis and the mean (M) 
and 95% confidence interval (CI) of total PEth concentrations in social drinkers  
(DAI ≤ 60 g/die; M = 0.288 µM; CI 0.208–0.367 µM) and heavy drinkers (DAI > 60 g/die; 
M = 3.897 µM; CI 2.404–5.391 µM) were calculated. The present analysis demonstrates a 
good clinical efficiency of PEth for detecting chronic heavy drinking. 
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1. Introduction 
Alcohol abuse and dependence are globally prevalent disorders, which span various  
socio-demographic groups and produce a broad range of secondary injuries and diseases [1,2]. 
Objective clinical and biochemical tests for characterizing the drinking pattern, quantifying the 
amount of daily ingested ethanol, and efficiently detecting alcohol-induced disorders are critically 
needed in both treatment and research areas [3,4].  
Guidance on the investigation of suspected alcohol dependence or abuse includes symptoms, 
medical history, self-report forms, special questionnaires, clinical examination and biochemical 
investigations. Detailed efforts have been made to construct interview formats that correctly quantify 
alcohol intake, such as the “Alcohol Use Disorders Identification Test Consumption” (AUDIT-C) [5], 
the CAGE questionnaire [6], or which include reports from collateral individuals. These approaches 
exhibit, however, limitations in the forensic setting, where individuals are motivated to deny or 
minimize the magnitude of their drinking behavior in order to mitigate the professional and legal 
ramifications of alcohol abuse [7,8]. 
The limited diagnostic efficiency of self-reports and the difficulty in assessing alcohol-drinking 
behavior from an objective point of view have led in the last decades to an intensive search for reliable 
biomarkers of chronic excessive drinking; these markers can be broadly divided into direct and  
indirect categories. Indirect biomarkers detect the effects of alcohol on organ systems or body 
chemistry, and generally comprise markers of alcohol-related toxic effects, including mean 
corpuscular volume (MCV), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and  
gamma-glutamyltransferase (GGT) [9,10]. More recent indirect markers examine ethanol-related 
biochemical changes in serum and comprise N-acetyl-beta-hexosaminidase (Beta-HEX), salsolinol,  
5-hydroxytryptophol (5-HTOL), plasma sialic acid index of apolipoprotein J (SIJ) and the widely used 
carbohydrate deficient transferrin (CDT) [11,12]. Direct markers include blood ethanol itself,  
as well as alcohol derivatives, such as acetaldehyde, acetic acid, fatty acid ethyl esters (FAEE), 
ethylglucuronide (EtG), ethyl sulphate (EtS), and phosphatidylethanol (PEth) [13–16].  
Among them, PEth in blood, and FAEE or EtG in hair, have attracted special attention as they are 
postulated to be highly specific and to roughly correlate with the ingested ethanol dose. Differently 
from FAEE and EtG, PEth in blood also seems to be promising for characterizing the drinking pattern 
(i.e., identifying binge drinking episodes) and differentiating light-moderate drinking from abstinence. 
For the above-mentioned reasons and given that all the identified review articles on the use of PEth 
in blood are based on descriptive data, a systematic review was conducted in order to summarize and 
better evaluate the diagnostic effectiveness of this marker in different clinical settings. 
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2. Results and Discussion 
As reported in Figure 1, the combined search with both MeSH terms and free-text protocols in the 
databases PubMed, Web of Science, Scopus and Ovid/Embase retrieved 916 records, 472 of which 
were excluded, as they were duplicates. Of the 444 records screened by title and abstract, 386 were 
manually excluded, because they did not fulfill the inclusion criteria. In particular, in those 
manuscripts, PEth was used for characterizing the function and properties of the enzyme 
phospholipase D, not as a biomarker of chronic alcohol consumption.  
Figure 1. Search strategy and paper selection for inclusion in the systematic review and/or 
in the meta-analysis. 
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Fifty-eight (58) potentially relevant papers were analyzed in full-text (Figure 1) and used to 
summarize the current evidence on: 
 The formation, distribution and degradation of PEth in human blood (Section 2.1); 
 The presence and distribution of different PEth molecular species in human blood (Section 2.2); 
 The most diffused and efficient analytical methods devoted to the identification and 
quantisation of PEth in human blood (Section 2.3); 
 The diagnostic efficiency of PEth as a clinical marker of chronic excessive drinking (Section 2.4); 
 The potential utility of PEth as a marker of heavy episodic drinking or binge drinking (Section 2.5). 
Twelve (2.7%) studies were included in the meta-analysis (Tables 1 and 2; Figure 2) since they 
presented integrable data on PEth concentration in human blood, and thus on the diagnostic efficiency 
of the marker in detecting harmful drinking behaviors. The mean and 95% confidence interval (CI) of 
total PEth concentration in social drinkers (mean 0.288 µM; CI 0.208–0.367 µM) and heavy drinkers 
(mean 3.897 µM; CI 2.404–5.391 µM) were reported in Figure 2, and discussed in Sections 2.4  
and 2.5.  
Figure 2. Schematic representation of the results of the meta-analysis performed on the 12 
papers described in Tables 1 and 2. The investigated populations were classified based on 
daily alcohol intake (DAI): social drinkers (DAI ≤ 60 g/die), and heavy drinkers  
(DAI > 60 g/die). The black diamond represents the calculated mean and 95% CI for each 
subgroup. Lower case letters in brackets refer to multiple groups of subjects included in the 
selected studies (see Table 1). 
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Table 1. The features of the 12 selected papers (study, year, main aim of interest, inclusion and exclusion criteria, and duration of the follow 
up) and the investigated populations (number of subjects, mean age, race, comorbidities, clinical setting, subject stratification, and type of 
controls used) are here summarized. 
Study Year 
Features of the study Investigated population
Main aim of 
interest 
Inclusion 
criteria Exclusion criteria 
Duration 
of 
follow-up
Number of Subjects Mean Age (Ys) * Race Comorbidities
Clinical 
setting Subjects stratification 
Type of 
controls 
Aradottir 
et al.  2006 
Diagnostic 
sensitivity of 
PEth and 
correlation to 
ethanol 
consumption 
(last 14 days) 
Diagnosis of 
alcohol 
dependence 
based on 
DSM IV and 
ICD-10 
BrAC < 0.1 g/L 
 
Illicit Drugs 
 
Severe medical illness 
- 
66 actively drinking 
patients attending a 
programme of consultation 
for problematic drinking 
(55 M/11 F)
49.1 ± 9.9 
- - OutpatientsInpatients 
By timeline follow-back:
“Low” < 40 g (n = 10)
- 
“Moderate” 40 to 80 g (n = 28) 
“High” 80 to 200 g (n = 60) 
78 patients admitted to a 
detoxification unit  
(68 M/10 F) 
52.9 ± 8.5 “Very High” > 200 g (n = 43) 
Comasco 
et al.  2009 
Comparison of 
diagnostic 
efficiency of 
PEth to 
clinical 
interview in 
detecting high 
alcohol 
consumers 
Students 
with deviant 
behaviour as 
reported by 
the Survey 
of 
Adolescent 
Life in 
Vestmanland 
- - 200 adolescent students (57 M/78 F) - - - Outpatients
By semistructured interview: 
 
(a) Low alcohol consumption  
(n = 96): consuming alcohol < 
2/mo and 
never, seldomly, or occasionally 
became intoxicated, or 
intermediate 
frequency alcohol consumers 
who never or seldomly became 
intoxicated 
 
(b) High alcohol consumption  
(n = 104) are “cases”: consuming 
alcohol ≥ 2/mo and always or 
almost always became drunk 
- 
Kip et al. 2008 
Investigate the 
diagnostic 
performance 
of PEth 
Negative 
BAC 
Age < 18 y 
BAC > 0.1g/L 
Recent use of illicit 
drugs, Pain ≥ 3 on 
Visual Analogue Scale,
Liver cirrhosis (Child B 
or C) and renal 
diseases, 
Mental illness,  
non-fluency of German 
language, police 
custody or inability to 
give informed consent 
- 
52 Male patients presented 
at the Emergency room 
with angina pectoris (ICD 
10 I20) or gastrointestinal 
complaints (ICD 10 K92.9)
 
AUDIT < 8 (n = 52)
61 (IQR 
39–66) 
- 
Smokers 28.8%
Outpatients
By AUDIT: 
AUDIT < 8 
(n = 52) 
- 22 Male patients presented 
at the Emergency room 
with angina pectoris (ICD 
10 I20) or gastrointestinal 
complaints (ICD 10 K92.9)
 
AUDIT ≥ 8 (n = 22)
52 (IQR 
38–64) Smokers 50% 
AUDIT ≥ 8 
(n = 22) 
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Table 1. Cont. 
Study Year 
Features of the study Investigated population
Main aim of 
interest 
Inclusion 
criteria 
Exclusion 
criteria 
Duration 
of 
follow-up
Number of Subjects Mean Age (Ys) * Race Comorbidities
Clinical 
setting 
Subjects 
stratification 
Type of 
controls 
Nalesso 
et al.  2011 
Correlate PEth 
to self-reports 
on alcohol 
assumption 
- BAC  < 0.1 g/L - 
11 Heavy drinkers admitted to a 
detoxification unit (7 M/4 F)
49 (IQR 
37–57)# 
- - 
Inpatients 
- Intergroup 8 Social drinkers (5 M/3 F) 42 (IQR 32–56)# Outpatients 
10 Teetotallers (6 M/4 F) 32.5 (IQR 27–39)# Outpatients 
Stewart 
et al.  2009 
Evaluate the 
relationship 
between PEth 
and recent 
drinking in 
patients with 
liver disease 
and 
hypertension 
Recent 
drinking 
Cognitive 
dysfunction 
precluding 
informed 
consent 
 
Abstainers 
- 
21 Liver disease patients  
(13 M/8 F) 
50  
(33–64)$ 
6 Hispanic 
white 
15  
non-Hispanic 
white 
21 Liver disease 
with Model for 
End-Stage Liver 
disease 16 
 (6–32)$; 5 with 
chronic 
Hepatitis C
Inpatients 
and 
Outpatients 
By average drinks 
per day  
(each drink = 14 g): 
 
<14 gr (n = 17)
- (14 ≤ x ≤ 42) g 
(n = 14) 
21 Hypertension patients  
(15 M/6 F) 
60  
(44–74)$ 
12 Hispanic 
white 
9  
non-Hispanic 
white
- ≥ 42 g 
(n = 11) 
Varga 
et al.  1998 
Investigate 
PEth levels 
after a limited 
ethanol intake 
Abstainers or 
“small 
amount” 
alcohol 
consumers 
- 21 days 17 Population with no or limited alcohol intake (11 M/6 F) 
25–47$ 
- - Outpatients 
5 abstainers  
(3 M/2 F) 
- 
19–31$ 12 social drinkers (8 M/4 F) 
Stewart 
et al.  2010 
Evaluate the 
relationship 
between blood 
PEth and 
alcohol use in 
reproductive 
age women 
Generally 
healthy 
women 
 
Age 18–35 ys 
 
Self-reported 
consumption 
of any 
amount on at 
least two 
days/wk 
Pregnant 
women and 
abstainers 
- 80 healthy women (80 F) 26 (IQR 23–30) 
71  
Non-Hispanic 
white 
6  
Non-
Hispanic-
black 
3 Others 
- Outpatients 
By average drinks 
per day 
 
>1 (14 g) (n = 64)
- 
>2 (28 g)
(n = 28)
All the cases 
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Table 1. Cont. 
Study Year 
Features of the study Investigated population
Main aim of 
interest Inclusion criteria 
Exclusion 
criteria 
Duration 
of 
follow-up
Number of Subjects Mean Age (Ys) * Race Comorbidities
Clinical 
setting 
Subjects 
stratification 
Type of 
controls 
Wurst  
et al. 
[45] 
2010 
Determine the 
correlation of PEth 
to self-reports 
Alcohol dependent 
detoxification 
patients  
(ICD 10 F10.25) 
Severe liver, 
renal and brain 
diseases, 
metabolic 
disorders, intake 
of illicit drugs, 
BAC < 0.1 g/L
28 days 
57 alcohol dependent 
detoxification 
patients (48 M/9 F) 
43.6 ± 10.4 - - Inpatients - - 
Wurst  
et al. 2004 
Evaluate the effect 
of using a low cut-
off to identify 
heavy 
drinking/alcohol 
dependence by 
PEth in whole 
blood
Meeting ICD 10 
criteria for  
alcohol-dependence
- - 18 detoxification patients (14 M/4 F) 
44  
(24–55)$ - 
Smoked 
cigarettes per 
day: 
20 ± 12.6 
Inpatients - - 
Wurst  
et al. 2012 
Explore 
Sensitivity and 
Specificity of PEth 
Meeting ICD 10 
F10.25 criteria - 28 days 
5 alcohol dependent 
patients (5 M/0 F) 
40 (IQR 
36–58)# - - Inpatients - - 
Marques 
et al. 2009 
Identify alcohol 
biomarkers related 
to driver’s BAC 
patterns from IIDs 
With IIDs (ignition 
lock at 0.04 g/dL) - 8 months 
534 DUI offenders 
(464 M/70 F): 
208 alcohol 
dependent 
64 alcohol abusers 
38.7 ± 11.5
91% 
Caucasian
9% 
Others 
- Outpatients
By fail rates at 
interlock BrAC test: 
0 lockouts (n = 136)
- 0 < lockouts ≤ 1.45% 
(n = 268)
> 1.45% lockouts 
(n = 104)
Varga  
et al. 2000 
Investigate 
elimination 
kinetics of PEth 
Chronic alcoholics 
admitted to a 
detoxification unit 
- 
- 6 Chronic alcoholics (6 M/0 F)
- - - Inpatients - - 
7 days 
15 Chronic 
alcoholics  
(13 M/2 F) 
* Data are reported as Mean (M) ± Standard Deviation (SD), or Median (Me) with Interquartile Range (IQR) according to the type of statistical distribution; - = Not reported; $ Total range is reported; # Calculated 
from the reported data; wk = week/s; mo = month/s; ys = years; BAC = Blood Alcohol Concentration; BrAC = Breath Alcohol Concentration; IIDs =Ignition Interlock Devices; DUI = Driving Under the Influence 
of alcohol; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders IV; AUDIT = Alcohol Use Disorders Identification Test; SRC = Self-Reported Consumption; PEth = Phosphatidil-Ethanol.  
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Table 2. Data on the frequency and amount of alcohol consumption of the subjects recruited in the 13 selected papers (methods for estimating 
alcohol use, mean daily alcohol consumption before test, timing of blood sampling and analysis), the analytical method used, the mean blood 
concentrations of total PEth, and the diagnostic efficiency of the marker (sensitivity, specificity, positive and/or negative predictive value)  
are presented. 
Study Year
Alcohol assumption PEth Determination
Methods for 
estimating 
alcohol use 
Daily Mean 
Alcohol 
consumption 
before test (g/die) 
Timing of 
blood 
retrieval 
Biological 
assessment 
before 
blood 
retrieval
Type 
of 
sample
Form of 
Measured 
PEth 
Analytical 
method 
LOQ # 
Cut-off **
Concentration 
µM Sensitivity Specificity PPV NPV
Other 
markers 
Aradottir 
et al.  2006
Timeline 
follow-back  
(14 days) 
103 ± 64 
Outpatients 
 
204 ± 126 
Inpatients Single retrieval 
Negative 
BrAC 
within 10 
previous 
hours 
Whole 
Blood 
Total 
PEth 
HPLC-
ELSD 
0.22 µM 
#** 
3.4 ± 2.6 
Outpatients 
7.7 ± 3.2 
Inpatients 
98% 
Outpatients
100% 
Inpatients 
- - - 
%CDT 
GGT 
MCV 0–40$ 100%°
- - - 40–80$ 96.9%°80–200$ 100%°
>200$ 100%°
Comasco 
et al.  2009
Survey of 
adolescent life 
in Vestmanland 
(1 last year) 
 
Semi-structured 
interview 
M = 6.2° 
F = 5.5° 
(daily mean during 
the last year) 
Single 
retrieval - 
Whole 
Blood 
Total 
PEth 
HPLC-
ELSD 
0.30 µM 
#** 
High alcohol 
consumers testing 
positive 
(n = 9) 
0.4 (0.25–0.71)&$
9% 96% 69% 49% FAEE 
Varga  
et al.  1998
Self Reported 
Consumption 
(3 weeks) 
47 g (M) or 32 g (F) 
(n = 5) 
Hours: 0.5 
– 1 – 2 - 4
- Whole blood 
Total 
PEth 
HPLC-
ELSD 
0.8 µM 
#** 
- 
- 100% - - CDT, GGT 
Days:
1 <LOQ 
3 <LOQ
5 <LOQ
63.5 ± 25.3 (n = 12) 
Days:
1 <LOQ
18 1.4 ± 0.6°
21 1.3 ± 0.5°
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Table 2. Cont. 
Study Year
Alcohol assumption PEth Determination
Methods for 
estimating 
alcohol use 
Daily Mean Alcohol 
consumption before 
test (g/die) 
Timing 
of blood 
retrieval
Biological 
assessment 
before 
blood 
retrieval
Type of 
sample 
Form of 
Measured 
PEth 
Analytical 
method 
LOQ # 
Cut-off **
Concentration 
µM Sensitivity Specificity PPV NPV
Other 
markers 
Kip  
et al.  2008
AUDIT 
 
Self Reported 
Consumption 
(1 week) 
20 (IQR 0–43) 
Single 
retrieval 
Negative 
BAC 
Whole 
blood 
Total 
PEth 
HPLC-
ELSD 
0.22 µM # 
0.0 (IQR 0.0–0.35) 
- - - - 
%CDT 
GGT 
MCV 
EtG in 
serum 
and 
urine 
60 (IQR 43–100) 0.33 (IQR 0.0–1.49) 
Nalesso 
et al.  2011
Self Reported 
Consumption 
(1 week)^ 
10 (IQR 9–15)° Single 
retrieval 
Negative 
BAC 
Whole 
blood 
17 PEth 
molecular 
species 
LC/HRMS
0.001 µM 
# 
2.8 ± 1.9°
100% - - - - 9 (IQR 4.5–13.5)° 0.021 ± 0.033°
0° <LLOQ°
Stewart 
et al.  2009
Self Reported 
Consumption 
(2 weeks) 
11.8 (IQR 0–51.8)° 
Single 
retrieval - 
Whole 
blood 16:0/18:1 
LC/MS-
MS 
0.03 µM # 
0.06 (IQR 0–0.06)°
- - - - - 
0.14 (IQR 
0.08–0.29)°26.7 (IQR  
10.1–38.5)° 0.98 (IQR 0.47–1.71)°
Stewart 
et al.  2010
Self Reported 
Consumption 
(2 weeks) 
25.4 (IQR  
14.6–98.4)°
Single 
retrieval - 
Whole 
blood 16:0/18:1 
LC/MS-
MS 
0.03 µM # 
<14 g/day
0.02 ± 0.04° 61% 95% 
- - - 44.2 (IQR  28.4–98.4)°
(14 < X < 28) g/day
0.07 ± 0.08° 32% 95% 
23 (IQR 15.1–38.1)° >28 g/day0.19 ± 0.18° - - 
Wurst 
et al.  2010
Timeline 
follow-back 
(1 week) 
or 
AUDIT 
 
207.4 ± 115.9 
Days: 1
- Whole blood 
Total 
PEth 
HPLC-
ELSD 
0.30 µM 
#** 
4.7 ± 4.97 100%
- - - 
%CDT 
GGT 
MCV 
3 3.09 (IQR 0.81-5.15)°& 93.7% 
5 2.42 (IQR 0.78–4.24)°& 94.4% 
7 1.69 (IQR 0.55–2.9)°& 94.1% 
14 0.88 (IQR 0.18–1.69)°& 66.7% 
28 0.81 (IQR 0.0–2.12)°& 25% 
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Table 2. Cont. 
Study Year
Alcohol assumption PEth Determination
Methods for 
estimating alcohol 
use 
Daily Mean 
Alcohol 
consumption 
before test 
(g/die)
Timing 
of blood 
retrieval
Biological 
assessment 
before 
blood 
retrieval
Type of 
sample 
Form of 
Measured 
PEth 
Analytical 
method 
LOQ # 
Cut-off ** 
Concentration
µM Sensitivity Specificity PPV NPV
Other 
markers 
Wurst  
et al.  2004
Timeline follow-
back 
(1 month)
148 (32–
253.3)$° 
Single 
retrieval - 
Whole 
blood 
Total 
PEth 
HPLC-ELSD 
0.30 µM #** 
0.0037 (IQR 
0.00063–
0.00868)°
100% - - - FAEE 
Wurst  
et al. 2012
Self Reported 
Consumption 
(1 week) 
 
AUDIT 
240 (IQR  
160–352)° 
Days:
1
- Whole blood 
Total 
PEth 
HPLC-ELSD 
0.22 µM #** 
4.40 ± 2.45°
100% - - - 
MCV, GGT, 
SIJ, UEtG, 
UEtS 
3
7 2.34 ± 1.57°
10
14 1.28 ± 0.67°
21 0.77 ± 0.35°
28 0.36 ± 0.25°
Marques 
et al. 2009
TLFB (30 days) 
DSM-IV 
C-DIS (Module R) 
AUDIT 
DRINC 
TRI 
17.2 ± 17.22 
(n = 120) 
1st  
day – 8th 
Month 
- Whole blood 
Total 
PEth 
HPLC-ELSD 
0.22 µM #** 
0.43 ± 0.51 
- - - - 
MCV, ALT, 
AST, GGT, 
%CDT, 
FAEE hair, 
ETG urine, 
ETS urine, 
ETG hair 
20.7 ± 25.5 
(n = 243) 0.61 ± 0.61 
29.55 ± 25.2 
(n = 99) 1.45 ± 1.17 
Varga  
et al. 2000 - 
- - 
Negative 
BrAC 
Whole 
blood 
Erythrocytes
MN 
leukocytes 
PMN 
leukocytes 
Plasma 
Total 
PEth 
HPLC-ELSD 
0.22 µM #** 
D1: 2.5 ± 0.9 
(n = 6)
- - - - CDT, GGT 150–300 
(range) 
Days:
1
D1: 5.1 ± 4.7 
(n = 15)
3 D3: 3.9 ± 2.8° (n = 13)
5 D5: 2.5 ± 2.2° (n = 9)
7 D7: 2.4 ± 2.5° (n = 10)
* Data are reported as Mean (M) ± Standard Deviation (SD), or Median (Me) with Interquartile Range (IQR) according to the type of statistical distribution; & Mean; $ Total range is reported; £ starting from the 
end of controlled alcohol administration; # LOQ; ^ As supplied by the Authors; ° Calculated from reported data; ** Cut-off; - = Not reported; BAC = Blood Alcohol Concentration; BrAC = Breath Alcohol 
Concentration; TLFB = Time-Line Follow-Back; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders IV; C-DIS = Computerized Diagnostic Interview Schedule; AUDIT = Alcohol Use Disorders 
Identification Test; DRINC = Drink Inventory of Consequences; TRI = Temptation and Restraint Inventory; TLC = Thin Layer Chromatography; LOQ = Limit of Quantification; HPLC = High Pressure Liquid 
Chromatography; PPV = Positive Predictive Value; NPV = Negative Predictive Value; LC = Liquid Chromatography; MS = Mass Spectrometry; ELSD = Electro-Light Scattering Detector;  
PEth = Phosphatidil-Ethanol; CDT = Carbohydrate Deficient Tranferrin; GGT = Gamma-Glutamyl Transpeptidase; MCV = Mean Corpuscolar Volume; AST = Aspartate Transaminase; ALT = Alanine 
Aminotransferase; GCDT = Gamma-CDT index(1.35 × ln CDT+0.8 × ln GGT); HRMS = High Resolution Mass Spectrometry; PMN = Polymorphonuclear cell; ETG = Ethyl-Glucuronide; ETS = Ethyl-Sulphate; 
FAEE = Fatty Acid Ethyl Esters; UETS = Urinary Ethyl Sulphate; UETG = Urinary Ethyl Glucuronide. 
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2.1. Phosphatidylethanol Definition, Formation and Degradation  
Phosphatidylethanol (PEth) is an abnormal cellular membrane phospholipid and was discovered for 
the first time in mammalians in 1983, being detected in the brain, kidney, liver, skeletal muscle, and 
heart of rats chronically exposed to ethanol [17–21].  
2.1.1. PEth Formation Mechanism  
The formation of PEth is catalyzed by phospholipase D (PLD), an ubiquitary enzyme [20,22–24] 
normally devoted to the hydrolysis of phosphatidylcholine (PC) to phosphatidic acid (PA). PLD has a 
high affinity for short chain alcohols (100–1000-fold higher than for water). In the presence of ethanol, 
it promotes a transphosphatidylation reaction, with the production of PEth [23,25]. The expression of 
PLD varies dramatically among different animal species and also among the tissues of a single 
organism [26,27]. In humans, two different isoforms of the enzyme (PLD1 and PLD2), sharing 50% of 
the DNA sequence, have been genetically and functionally characterized. PLD1 has a perinuclear 
distribution and displays a very low basal activity, requiring a protein kinase C activation; PLD2 is 
localized in the cellular membrane and is constitutively active [28,29]. Both PLD1 and PLD2 catalyze 
the formation of PEth in human red blood cells [26–31]. 
2.1.2. PEth Formation in Human Blood  
It has been observed that the in vitro incubation of whole human blood with ethanol for 24 h (EtOH 
concentration varying between 50 and 100 mM) induces the formation of PEth, and that the EtOH 
concentration and the incubation time are directly proportional to the quantity of PEth produced. An 
activator of the protein kinase C added to the mixture triplicates the generated quantity of PEth [32]. 
No correlation between hematological indexes (red blood cell count, mean corpuscular volume, 
hematocrit) and the rate of PEth formation has been found [32].  
Several studies on blood collected from mice, rat, ferret and pig have excluded the presence and the 
in vitro production of PEth in animal red blood cells (RBCs); thus, human RBCs seem to be peculiar in 
forming PEth in vitro in the presence of ethanol [32,33]. This characteristic represents an important 
drawback of PEth as a marker of chronic alcohol abuse: samples collected when the blood ethanol 
concentration (BAC) is higher than 0.1 g/L can generate false positive results due to the neo-formation 
of PEth in vitro (in the post-sampling period), which can occur at room temperature (16 °C–20 °C), but 
also at −20 °C, being slower at +4 °C [32]. Only at −80°C can the formation process be considered 
drastically inhibited [32–34]. 
2.1.3. PEth Degradation Mechanism  
Another important and peculiar characteristic of human RBCs is the incapacity of efficiently 
degrading PEth, probably due to the absence of phosphatidylcholine phospholipase C (PLC)  
activity [32–35]. PEth elimination, with a half-life (t/2) varying between 0.5 and 2 h, has been 
demonstrated in several human cellular systems, such as pancreatic islets [36], hepatocytes (HepG2 
and C6 cells) [36–38], and neutrophils, but not in RBCs [32,38]. The molecular mechanism of PEth 
elimination has not yet been fully elucidated; although phospholipase A2 and PLC in vitro release 
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arachidonic and palmitic acid from PEth [20,39], there is still a lack of evidence that phospholipases 
are involved in the in vivo PEth degradation. What is clear is that in human RBCs there is a 
disproportion between PEth formation and degradation rates, causing PEth to accumulate in the 
cellular membranes, an accumulation that suggests a potential use of PEth for detecting chronic 
exposure to ethanol. 
2.1.4. PEth Degradation in Human Blood  
In clinical studies conducted on chronic heavy drinkers, PEth was found to be detectable in blood 
up to 28 days after sobriety [32,40–46]. In 15 alcoholics following a detoxification program, the mean 
half-life of blood PEth was 4.0 ± 0.7 days with a range of 3.0–5.3 days [47]. The kinetics of 
elimination was well-approximated by a one-compartment model. More recently, this degradation 
kinetics has been confirmed on 57 alcohol-dependent subjects following a detoxification program [45]. 
PEth decreased over time with a half-life of about 3–5 days and was detectable in 64.3% of the cases 
after 28 days of sobriety [45]. Additionally, it has been demonstrated that sex, gender, age and body 
mass index do not influence the normalization rate of PEth [45].  
In a recent experiment during which, after three weeks of abstinence, 11 social drinkers were 
exposed to an amount of ethanol of 1 g/Kg for five consecutive days (daily alcohol intake ranging 
between 67 and 109 g/die), and then remained abstinent for 16 days, undergoing regular and scheduled 
blood sampling, the mean half-life of PEth ranged from 4.5 to 10.1 days in the first week and from 5.0 
to 12.0 days in the second week [48]. 
2.2. Phosphatidylethanol Molecular Species 
Since the very early studies conducted on rats chronically exposed to ethanol [17–22,49] it has been 
observed that PEth is not a single molecule, but a group of glycerophsopholipid homologues with a 
common phosphoethanol head group onto which two long carboxylic acid side chains, typically 
containing from 14 to 22 carbon atoms with different grades of insaturation (0–6 double bonds), are 
attached [50–52]. 
These homologues are commonly named in the form “PEth A:B/C:D” where A and C indicate the 
number of carbons in the carboxylic side chains, whereas B and D indicate the number of double 
bonds in each side chain [34]. 
Fast atom bombardment-mass spectrometry experiments on PEth, formed after bradykinin or 
phorbol ester PLD stimulation in pheocromocytoma cells (PC12), revealed that the molecular species 
of the generated PEth were almost identical to those of PC, consistent with this lipid being the 
substrate of PLD [51]. Additionally, using neuroblastoma cells (NG 108-15) it has been demonstrated 
that the addition of polyunsaturated fatty acids to the medium induced similar changes in the fatty acid 
composition of PC and PEth [52,53].  
In one of the studies by Alling et al. [17] on the distribution of PEth in the organs of rats chronically 
treated with ethanol, significant inter-organ differences in the fatty acid composition of PEth have been 
highlighted: brain PEth contained high proportions of palmitic (16:0) (28%) and oleic (18:1) (34%) 
acids with a 10% of polyunsaturated fatty acids (mainly arachidonic acid, 20:4), whereas liver PEth 
contained more stearic acids (18:0) and less palmitic acids (16:0) [17].  
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Only in recent times was the characterization of PEth molecular species in human blood  
performed, through highly sensitive liquid chromatography multiple mass spectrometry methods  
(LC-MS/MS) [50,54–57]. In blood collected from heavy drinkers PEth 16:0/18:1 and 16:0/18:2 have 
been demonstrated to be the predominant molecular species accounting on average for 37%–46% and  
26%–28%, respectively, of total PEth in blood [50,57]. Owing to inter-individual variations, PEth 
16:0/18:2 was sometimes the major form, whereas PEth 16:0/20:4 constituted about 8%–13% of total 
PEth, and PEth 18:1/18:1 and 18:0/18:2 taken together constituted about 11%–12% of total PEth. The 
species 16:0/16:0, 16:0/20:3, 18:0/18:1, 16:0/20:3 and 18:1/18:2 had a lower blood concentration, each 
one accounting for about 1%–5% of total PEth [50,57]. Diet was suggested to be the main factor 
determining the fatty acid pattern in PC and PEth, although the influence of genetic determinants, 
drinking pattern and metabolic disorders needs to be further clarified. 
The numerous combinations of chain length and double bonds enable the formation of a very large 
theoretical number of different PEth species and so far 48 homologues have been identified in  
post-mortem human blood [55]. Although inter-individual differences in the relative abundances of 
PEth homologues do exist, the preliminary data available suggest that 5 molecular species (16:0/18:1, 
16:0/18:2, 16:0/20:4, 18:1/18:1, 18:1/18:2) could constitute more than 80% of total PEth. 
2.3. Analytical Techniques and Methods for PEth Identification and Quantization in Blood  
For PEth determination, venous blood should be collected in tubes containing ethylenediamine 
tetra-acetic acid (EDTA) and the sample should not be centrifuged [34]. Blood samples for PEth 
analysis have proved to be stable for 24 h at room temperature and for 3 weeks at +4 °C [32,58]. For 
longer periods of storage, whole blood should be frozen in a plastic tube and kept at −80 °C, to avoid 
any in vitro formation [34]. 
Several analytical strategies have been utilized so far for quantifying total PEth concentration in 
blood, mainly based on chromatographic or electrophoretic separation methods, as reported below. 
 Thin layer chromatography (TLC) [17–20,59].  
 High performance liquid chromatography (HPLC) coupled to an evaporative light-scattering 
detector (ELSD) [34,47,60–62]. 
 Gas-chromatography coupled to mass spectrometry [63]. 
 Non-aqueous capillary electrophoresis (NACE) [64,65]. 
 Immunoassay with PEth-specific monoclonal antibodies [66,67]. 
Thin layer chromatography (TLC) is a manual semi-quantitative method with limited sensitivity 
and throughput and was the very first method used for identifying PEth in animal tissues [17,18], 
quickly judged unsuitable for further experimental studies. The first and only gas-chromatographic 
method reported in the literature was developed for the detection of two derivatization products of 
PEth, ethyl bis (trimethyl-silyl)-phosphate and tris (trimethyl-silyl)-phosphate; probably due to a lack 
of specificity of the monitored derivatization products, this method has never been applied to the 
analysis of clinical samples [63].  
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Similarly, to the best of our knowledge, the immunochemical method based on the anti-PEth 
antibodies 2B1 e 2E9 generated with the traditional hybridoma technique, capable of detecting in vitro 
formed PEth, has not yet found a clinical application [66,67]. 
The two electrophoretic methods based on non-aqueous capillary electrophoresis, either coupled to 
an UV [64] or to a mass spectrometric detector [65] have also found very limited clinical application.  
On the contrary, the HPLC-ELSD method is actually the most utilized in clinical toxicology. 
Briefly, whole blood together with the internal standard (phosphatidylbutanol 18:1/18:1) are extracted 
with 2-propanol and hexane, followed by the quantification of PEth in the extract on an HPLC  
system equipped with an evaporative light scattering detector (ELSD) and with PEth 18:1/18:1 as  
calibrator [47,60–62]. 
More recently several liquid chromatography mass spectrometry (LC-MS) or multiple mass 
spectrometry methods (LC-MS/MS) have been developed for the identification of PEth homologues in 
blood, the majority of which employ electrospray ionization (ESI) for MS coupling [50,55–58], 
although time-of-flight (TOF) mass spectrometry has also been proposed [68]. Also a LC-MS/MS 
method for the analysis of PEth 16:0/18:1 and 18:1/18:1 on dried blood spots, which exhibited a good 
correlation with parallel determinations on fresh blood, has been developed and validated [69]. 
All these novel mass spectrometric methods exhibit a considerably higher analytical sensitivity 
(more than two orders of magnitude) and shorter turnaround time with respect to HPLC-ELSD, and are 
capable of identifying PEth species also in blood collected from social drinkers [57,70–73]. 
A considerable limitation of the above-mentioned methods, however, is the absence of 
commercially available reference substances for PEth analogs (at the moment only PEth 16:0/16:0, 
16:0/18:1 and 18:1/18:1 are available), complicating the validation process, and hindering the diffusion 
of these methods in clinical and forensic toxicology laboratories. Zheng and coworkers have solved the 
problem by preparing in house deuterium-labeled PEth analogs for PEth 16:0/18:1 and PEth 16:0/18:2. 
This commendable effort is however too complex and time-consuming to leave the research arena and 
enter routine laboratory practice [58]. 
2.4. Diagnostic Efficiency of PEth as a Clinical Marker of Chronic Excessive Drinking 
Four out of twelve articles included in the present meta-analysis are clinical trials involving 
inpatients with a diagnosis of alcohol-dependence based on the Diagnostic and Statistical Manual IV-R 
(DSM IV-R) or the International Classification of Diseases (ICD-10) criteria, who underwent a 
detoxification program (see Table 1). These studies are generally aimed at evaluating the diagnostic 
efficiency of PEth in comparison to clinical interviews, questionnaires and/or other traditional markers 
of harmful drinking, and at correlating the concentration of PEth to the amount of ethanol ingested in 
the previous 2–4 weeks [40,43–47,57,70,72–77]. Only one of those studies used an intergroup control [57], 
the rest being uncontrolled trials.  
The concentrations of total PEth in alcohol dependent subjects admitted for detoxification vary 
significantly in the considered clinical studies (range: 0.0–7.7 μM; see Table 2). With respect to the 
mean values and 95% CI of PEth concentrations reported in the meta-analyzed papers (see Table 2 and 
Figure 2), the heavy drinkers group (Daily Alcohol Intake—DAI > 60 g) is well separated from the 
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social drinkers, displaying a mean concentration one order of magnitude higher than the remaining 
groups (heavy drinkers = 3.897 µM; social drinkers = 0.288 µM).  
At the present time, the international scientific community has not yet established a cut-off value 
for PEth concentration in blood to be used for differentiating an acceptable social ethanol intake (<40 g 
for males and <20 g for females, according to the World Health Organization parameters), from an  
at-risk-alcohol-use (40–60 g/die) and chronic excessive drinking behavior (>60 g/die).  
Nine of the above-mentioned clinical trials used HPLC-ELSD for total PEth quantification in blood 
utilizing as an interpretative cut-off the lower limit of quantification (LOQ) of the analytical method 
used for PEth determination, that is: 0.22 μM [40,46,47,70,77], 0.30 μM [44,45,75] or 0.8 μM [43]. 
With the above-mentioned cut-offs, the diagnostic sensitivities of PEth were very high, varying from 
98% [40] to 100% [44–46,57].  
In Sweden, 0.7 μM is currently used as the routine clinical threshold [50], although that value has 
not yet been approved at a supranational level [78]. 
Regarding clinical specificity in differentiating alcohol-dependent subjects from social drinkers 
and/or abstainers, the available controlled trials have all obtained a 100% value [42,57,73]. This 
absolute specificity of the biomarker can only be partly explained by the intrinsic characteristics of 
PEth, which is formed in blood only in the presence of ethanol. Potential bias of selection have to be 
considered, due to the fact that the case-control populations considered exhibited significant 
differences in the drinking pattern and in the amount of daily-ingested ethanol (see Table 1). 
Differing from the traditional indirect biomarkers used for diagnosing a chronic excessive drinking 
behavior (MCV, AST, ALT, GGT, and CDT), blood PEth concentration seems not to be influenced by 
age, gender, other ingested substances or non alcohol-associated diseases, such as hypertension, kidney 
and/or liver diseases [44–46,72]. For these reasons, PEth is considered to perform better than MCV 
and GGT, both in terms of sensitivity and specificity, for detecting chronic excessive drinking 
behaviors [40–43,45,46]. A few studies have also highlighted a slightly higher sensitivity of PEth, 
compared to the most selective indirect marker CDT [40,42,43]. 
Preliminary evidence does exist concerning a rough correlation between the amount of ethanol 
consumed in the previous two weeks and the concentration of PEth in blood [40,44,45,57], although 
observations of individual PEth formation rates [32] and recent studies on moderate drinkers indicate 
that it might not always be possible to link PEth concentration in blood to a precise drinking level [72,73]. 
2.5. PEth as a Potential Marker of Heavy Episodic Drinking or “Binge Drinking”  
An especially interesting question, which still needs to be answered, regards the quantity of ethanol 
that must be consumed for a certain time-period to give a positive blood PEth assay. Using the  
HPLC-ELSD method of analysis, it has been observed that a single ethanol dose of 30–47 g did not 
produce any measurable amounts of PEth in blood [43]. The threshold of total ethanol intake leading 
to a positive PEth assay was estimated at around 1000 g in three weeks, with a daily consumption of at 
least 50 g/die [43,45]. A recent drinking experiment, which employed a more sensitive LC-MS/MS 
method for the quantification of PEth 16:0/18:1, conducted on 11 healthy volunteers who drank  
50–109 g of ethanol/die, showed that the formation of PEth began immediately after the first 
assumption of alcohol (0.5–8 h) reaching a concentration of about 0.05–0.10 μM and then stagnated or 
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decreased when the blood alcohol concentration started to decline [48]. These results are certainly 
encouraging because they pave the way for novel potential applications of PEth in the diagnosis of 
excessive drinking episodes and/or “binge drinking” behaviors; at the same time, they do underline the 
compelling need to study large populations of social drinkers and teetotalers in order to determine 
whether an efficient cut-off can be established for differentiating teetotalers from social/moderate 
drinkers and “binge drinkers”. 
At the present time, only five studies have examined the characteristics of total PEth as a potential 
marker of “binge drinking” [72,73,75–77]; the small number of the investigated subjects, the 
variability of the clinical methods used to reconstruct the daily alcohol intake (see Table 1), and the 
diversity of the analytical methods employed for quantifying total PEth in blood (see Table 2) has not 
yet allowed any definitive conclusion to be drawn. Comasco et al. [75] have found a sensitivity of only 
9% for detecting a moderate alcohol consumption (>2 drinks/week) in 200 adolescent students from 
Vestmanland, with the limited clinical efficiency of PEth probably explained by the low sensitivity of 
the analytical method (HPLC-ELSD) and the subject stratification employed. 
Stewart and colleagues [73], examining 80 healthy women in reproductive age, have found that a 
PEth 16:0/18:1 concentration above 0.18 μM was highly specific for identifying women drinking more 
than 28 g per day, although a relevant degree of inter-individual variability was evident; this variability 
could only partly be explained by the different timing of assumption (with respect to blood sampling) 
and the different drinking patterns (regular moderate intake vs. episodic heavy drinking) [73]. 
Although being expensive, we do believe that only controlled drinking experiments over a period of  
2–3 weeks could highlight if and how PEth could be utilized as a marker of “binge drinking” or as a 
marker of absolute abstinence.  
3. Experimental Section  
3.1. Search Strategy 
In March 2012, one of the authors (GV) performed the systematic search of the literature searching 
Medline/PubMed, SCOPUS, Web of Science, and Ovid/Embase databases. The Medline search 
employed a complex search strategy including both “MeSH” and “free-text” protocols. More 
specifically, the following terms retrieved from the MeSH browser provided by Medline were utilized: 
(“Ethanol” [MeSH] OR “Alcohol Drinking” [MeSH]) AND “Phosphatidylethanol” [MeSH]. A 
multiple “free-text” search restricted to the fields “title/abstract” was performed combining by “AND” 
the entry terms “Alcohol” and “Phosphatidylethanol”. No temporal limits were utilized. Because of the 
interface limitation only the “free-text” protocol “((Phosphatidylethanol OR PEth) AND (Ethanol OR 
Alcohol))” was used for searches in Ovid/Embase, Web of Science (search field: “topic”), and 
SCOPUS (search fields: title/abstract, keywords). 
3.2. Paper Selection  
Paper selection was conducted independently by three reviewers (GV, RBB, AN), based on titles 
and abstracts of papers retrieved by the systematic search. The following inclusion and exclusion 
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criteria were adopted for review and meta-analytic purposes. Any discrepancy in the paper selection 
and data extraction was settled by consensus discussion. 
3.2.1. Inclusion criteria for review purposes.  
To meet the inclusion criteria for the present review, studies had to fulfill at least one of the 
following requirements:  
(A) Provide data on PEth concentration in human blood collected from alcohol dependent subjects, 
heavy drinkers, moderate drinkers, social drinkers or teetotalers. 
(B) Provide data on PEth concentration in fluids or tissues of animals chronically exposed to ethanol. 
(C) Describe an analytical method for the quantification of total PEth or PEth molecular species in 
human blood. 
3.2.2. Exclusion criteria for review purposes.  
Articles not fulfilling at least one of the previous requirements or characterizing the activity of 
phospholipase D (PLD) were excluded.  
In the case of doubtful classification based on solely title and abstract, the full text was retrieved. 
Whenever this was ineffective, the question was settled by consensus discussion. 
3.2.3. Inclusion criteria for meta-analytic purposes.  
To meet the inclusion criteria for the present meta-analysis, studies had to fulfill all the following 
requirements:  
(D) Fulfilling criterion A for Review purposes. 
(E) Reporting integrable data on blood concentrations of PEth in humans. 
(F) Reporting integrable data on the daily alcohol intake (DAI) of the subjects recruited in the study. 
3.2.4. Exclusion criteria for meta-analytic purposes.  
Articles not fulfilling all of the above-mentioned requirements, being commenting letters or 
reviews, reporting data not comparable/suitable for direct meta-analysis processing (i.e., inappropriate 
statistical formats) or not amenable by extraction or calculation/conversion from the published results 
or figures, were excluded.  
3.3. Data Extraction 
Data extraction was conducted independently by four authors (GV, RBB, AN, PF) and the data 
derived from the studies were collected in an electronic database, while two different authors (GC, 
SDF) verified the accuracy of the data extraction process, in order to minimize subjective judgment. 
The following items were collected from each study: authors, publication year, features of the study 
(main aims, inclusion and exclusion criteria, duration of the follow-up), characteristics of the 
investigated population (numbers of subjects, age, race, comorbidities, use of medications or 
assumption of illicit drugs, clinical setting, type of controls used), type and amount of alcohol 
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consumption (estimation of alcohol use, daily mean ingested ethanol, type of stratification if any, 
timing of sample collection, biological assessments before collection), analytical methods used for 
PEth analysis, type of measured PEth and concentrations, type of collected sample, clinical efficiency 
of PEth (sensitivity, specificity, positive predictive value, negative predictive value), and other markers 
used for detecting chronic excessive drinking. Any discrepancy in data extraction was settled by 
consensus discussion. 
In order to meta-analyze the distribution of PEth concentration with regard to the DAI, data were 
grouped into two categories, as follows, considering the mean or median of DAI for the classification 
of the drinking behavior.  
Category 1. Social drinkers (DAI ≤ 60 g). 
Category 2. Heavy drinkers (DAI > 60 g). 
Specifically, these categories were overlapping for some extreme values (ranging from 40 to 60 g), 
which represented the mathematical limits of the Standard Deviation or the Interquartile Range. This 
reflected the lacking of a shared threshold to discriminate DAI among groups. Nevertheless, the 
descriptive statistics of DAI also reported the most important indexes of central tendency (mean and 
median), which were markedly different between groups (Table 2), hence not impairing our analysis. 
3.4. Statistical Analysis 
One of the authors (RBB) performed the meta-analysis according to a previously published 
procedure [79,80]. Statistical analyses of continuous variables were performed using the weighted 
mean as the summary statistic reported with 95% confidence intervals. To allow inference to an 
external population, a random-effects model was used for purposes of meta-analysis in a conservative 
setting [79,81]. 
4. Conclusions  
The present systematic review demonstrates that total phosphatidylethanol, an abnormal 
phospholipid formed in the erythrocyte membrane exclusively in the presence of ethanol, exhibits high 
diagnostic sensitivity and specificity for detecting active chronic excessive drinking behaviors, with a 
regular daily alcohol intake (DAI) of more than 60 g. 
The mean values and confidence intervals of total PEth concentrations in blood of heavy  
(DAI > 60 g/die) and social drinkers (DAI ≤ 60 g/die) showed a significant statistical difference. These 
findings demonstrate a good clinical efficiency of PEth for detecting heavy drinking. 
The recent introduction of sensitive analytical methods based on liquid chromatography coupled to 
mass spectrometry detection, capable of effectively measuring single molecular species of PEth in 
blood in the nanomolar range, has opened promising new application fields for PEth, such as the 
identification of minute alcohol consumption (i.e., monitoring of abstinence), and the identification of 
heavy episodic drinking behaviors (i.e., “binge drinking”). However, large randomized trials are 
needed in order to ascertain if PEth is really effective in those diagnostic challenges. 
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Moreover, it is essential to set up international standards that properly define the characteristics of 
the alcohol biomarker PEth and harmonize the methodology used in both clinical and laboratory 
investigations. The following five issues certainly need to be addressed. 
1. Define the molecular species of PEth that should be determined in blood when a mass 
spectrometric analytical method is used; it needs to be clarified if PEth 16:0/18:1 and 16:0/18:2 
(the two most abundant homologues) are sufficient to resemble the total PEth concentration or 
whether it would be more appropriate to investigate and quantify multiple PEth molecular 
species; the data derived from our analysis suggest that at least 5 molecular species (PEth 
16:0/18:1, 16:0/18:2, 16:0/20:4, 18:1/18:1, 18:1/18:2) could be used. 
2. Develop and market commercial reference substances for the PEth molecular species identified 
by point 1. 
3. Arrive at a consensus on the most appropriate cut-off for differentiating social alcohol use from 
heavy drinking. 
4. Characterize the kinetics of formation and degradation of the identified PEth species in order to 
determine whether they might be used for monitoring abstinence. 
5. Verify the correlation of blood PEth concentration with the amount of ethanol ingested in the 
previous two weeks. 
Authors’ Contribution 
G.V. and R.-B.B. had full access to all the data in the study and take responsibility for the integrity 
of the data and the accuracy of the analysis.  
Study concept and design: G.V. (concept); R.-B.B (design).  
Acquisition of data: G.V. (systematic search); R.-B.B, G.V., A.N., P.F. (data extraction and 
database construction); G.C., S.-D.F. (accuracy check). 
Analysis and interpretation of data: R.-B.B.  
Drafting of the manuscript: G.V., R.-B.B., G.C.  
Critical revision of the manuscript for important intellectual content: S.-D.F.  
Statistical analysis: R.-B.B.  
Obtaining funding: Grant n. 60A07-9371/12 of the University of Padova.  
Administrative, technical, or material support: None.  
Other (specify): None. 
Acknowledgments 
The authors are grateful to Thomas Dewis for the precious language-editing. 
Conflict of Interest 
The authors declare no conflict of interest. 
Int. J. Mol. Sci. 2012, 13 14807 
 
 
References 
1. Domino, K.B.; Hornbein, T.F.; Polissar, N.L.; Renner, G.; Johnson, J.; Alberti, S.; Hankes, L. 
Risk factors for relapse in health care professionals with substance use disorders. JAMA 2005, 
293, 1453–1460. 
2. Li, T.K. Quantifying the risk for alcohol-use and alcohol-attributable health disorders: Present 
findings and future research needs. J. Gastroenterol. Hepatol. 2008, 23, S2–S8. 
3. Ferrara, S.D.; Bajanowski, T.; Cecchi, R.; Boscolo-Berto, R.; Viel, G. Bio-medicolegal scientific 
research in Europe: A comprehensive bibliometric overview. Int. J. Legal. Med. 2011, 125,  
393–402. 
4. Ferrara, S.D.; Bajanowski, T.; Cecchi, R.; Snenghi, R.; Case, C.; Viel, G. Bio-medicolegal 
guidelines and protocols: Survey and future perspectives in Europe. Int. J. Legal. Med. 2010, 124, 
345–350. 
5. Bradley, K.A.; DeBenedetti, A.F.; Volk, R.J.; Williams, E.C.; Frank, D.; Kivlahan, D.R.  
AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol. Clin. Exp. Res. 2007, 31, 
1208–1217. 
6. Ewing, J.A. Detecting alcoholism. The CAGE questionnaire. JAMA 1984, 252, 1905–1907. 
7. Ferrara, S.D. Alcohol, drugs and traffic safety. Br. J. Addict. 1987, 82, 871–883. 
8. Favretto, D.; Nalesso, A.; Frison, G.; Viel, G.; Traldi, P.; Ferrara, S.D. A novel and an effective 
analytical approach for the LC-MS determination of ethyl glucuronide and ethyl sulfate in urine. 
Int. J. Legal Med. 2010, 124, 161–164. 
9. Conigrave, K.M.; Degenhardt, L.J.; Whitfield, J.B.; Saunders, J.B.; Helander, A.; Tabakoff, B. 
CDT, GGT, and AST as markers of alcohol use: The WHO/ISBRA collaborative project.  
Alcohol. Clin. Exp. Res. 2002, 26, 332–339. 
10. Musshoff, F. Chromatographic methods for the determination of markers of chronic and acute 
alcohol consumption. J. Chromatogr. B 2002, 781, 457–480. 
11. Bortolotti, F.; de Paoli, G.; Tagliaro, F. Carbohydrate-deficient transferrin (CDT) as a marker of 
alcohol abuse: A critical review of the literature 2001–2005. J. Chromatogr. B 2006, 841, 96–109. 
12. Golka, K.; Wiese, A. Carbohydrate-deficient transferrin (CDT)—A biomarker for long-term 
alcohol consumption. J. Toxicol. Environ. Health B 2004, 7, 319–337. 
13. Favretto, D.; Nalesso, A.; Frison, G.; Viel, G.; Traldi, P.; Ferrara, S.D. No-discharge atmospheric 
pressure chemical ionization mass spectrometry of ethyl glucuronide and ethyl sulfate.  
J. Mass Spectrom. 2010, 45, 121–124. 
14. Hoiseth, G.; Morini, L.; Polettini, A.; Christophersen, A.; Morland, J. Ethyl glucuronide in hair 
compared with traditional alcohol biomarkers—A pilot study of heavy drinkers referred to an 
alcohol detoxification unit. Alcohol. Clin. Exp. Res. 2009, 33, 812–816. 
15. Litten, R.Z.; Bradley, A.M.; Moss, H.B. Alcohol biomarkers in applied settings: Recent advances 
and future research opportunities. Alcohol. Clin. Exp. Res. 2010, 34, 955–967. 
16. Bordignon, M.; Viel, G.; Peserico, A.; Alaibac, M. Non-alcoholic fatty liver disease, alcohol 
intake and psoriasis. J. Hepatol. 2010, 53, 587. 
17. Alling, C.; Gustavsson, L.; Anggard, E. An abnormal phospholipid in rat organs after ethanol. 
FEBS Lett. 1983, 152, 24–28. 
Int. J. Mol. Sci. 2012, 13 14808 
 
 
18. Alling, C.; Gustavsson, L.; Mansson, J.E.; Benthin, G.; Anggard, E. Phosphatidylethanol 
formation in rat organs after ethanol treatment. Biochim. Biophys. Acta 1984, 793, 119–122. 
19. Benthin, G.; Anggard, E.; Gustavsson, L.; Alling, C. Formation of phosphatidylethanol in frozen 
kidneys from ethanol-treated rats. Biochim. Biophys. Acta 1985, 835, 385–389. 
20. Gustavsson, L.; Alling, C. Formation of phosphatidylethanol in rat brain by phospholipase D. 
Biochem. Biophys. Res. Commun. 1987, 142, 958–963. 
21. Lundqvist, C.; Aradottir, S.; Alling, C.; Boyano-Adanez, M.C.; Gustavsson, L. 
Phosphatidylethanol formation and degradation in brains of acutely and repeatedly ethanol-treated 
rats. Neurosci. Lett. 1994, 179, 127–131. 
22. Gustavsson, L.; Moehren, G.; Hoek, J.B. Phosphatidylethanol formation in rat hepatocytes.  
Ann. N. Y. Acad. Sci. 1991, 625, 438–440. 
23. Kobayashi, M.; Kanfer, J.N. Phosphatidylethanol formation via transphosphatidylation by rat 
brain synaptosomal phospholipase D. J. Neurochem. 1987, 48, 1597–1603. 
24. Mueller, G.C.; Fleming, M.F.; LeMahieu, M.A.; Lybrand, G.S.; Barry, K.J. Synthesis of 
phosphatidylethanol—A potential marker for adult males at risk for alcoholism.  
Proc. Natl. Acad. Sci. USA 1988, 85, 9778–9782. 
25. Gustavsson, L. ESBRA 1994 Award Lecture. Phosphatidylethanol formation: specific effects of 
ethanol mediated via phospholipase D. Alcohol Alcohol. 1995, 30, 391–406. 
26. Colley, W.C.; Sung, T.C.; Roll, R.; Jenco, J.; Hammond, S.M.; Altshuller, Y.; Bar-Sagi, D.; 
Morris, A.J.; Frohman, M.A. Phospholipase D2, a distinct phospholipase D isoform with novel 
regulatory properties that provokes cytoskeletal reorganization. Curr. Biol. 1997, 7, 191–201. 
27. Steed, P.M.; Clark, K.L.; Boyar, W.C.; Lasala, D.J. Characterization of human PLD2 and the 
analysis of PLD isoform splice variants. FASEB J. 1998, 12, 1309–1317. 
28. Vinggaard, A.M.; Hansen, H.S. Bradykinin and vasopressin activate phospholipase D in rat 
Leydig cells by a protein kinase C-dependent mechanism. J. Endocrinol. 1993, 136, 119–126. 
29. Shukla, S.D.; Sun, G.Y.; Wood, W.G.; Savolainen, M.J.; Alling, C.; Hoek, J.B. Ethanol and lipid 
metabolic signaling. Alcohol. Clin. Exp. Res. 2001, 25, 33S–39S. 
30. Lundqvist, C.; Alling, C.; Aradottir, S.; Gustavsson, L. Agonist-stimulated and basal 
phosphatidylethanol formation in neutrophils from alcoholics. Alcohol. Clin. Exp. Res. 1994, 18, 
580–586. 
31. Magai, R.M.; Shukla, S.D. Metabolic fate of [14C]-ethanol into endothelial cell phospholipids 
including platelet-activating factor, sphingomyelin and phosphatidylethanol. J. Biomed. Sci. 2001, 
8, 143–150. 
32. Aradottir, S.; Moller, K.; Alling, C. Phosphatidylethanol formation and degradation in human and 
rat blood. Alcohol Alcohol. 2004, 39, 8–13. 
33. Aradottir, S.; Lundqvist, C.; Alling, C. Phosphatidylethanol in rat organs after ethanol exposure. 
Alcohol. Clin. Exp. Res. 2002, 26, 514–518. 
34. Isaksson, A.; Walther, L.; Hansson, T.; Andersson, A.; Alling, C. Phosphatidylethanol in blood 
(B-PEth): A marker for alcohol use and abuse. Drug Test Anal. 2011, 3, 195–200. 
35. Selle, H.; Chapman, B.E.; Kuchel, P.W. Release of choline by phospholipase D and a related 
phosphoric diester hydrolase in human erythrocytes. 1H spin-echo n.m.r. studies. Biochem. J. 
1992, 284, 61–65. 
Int. J. Mol. Sci. 2012, 13 14809 
 
 
36. Metz, S.A.; Dunlop, M. Production of phosphatidylethanol by phospholipase D phosphatidyl 
transferase in intact or dispersed pancreatic islets: Evidence for the in situ metabolism of 
phosphatidylethanol. Arch. Biochem. Biophys. 1990, 283, 417–428. 
37. Bruhl, A.; Faldum, A.; Loffelholz, K. Degradation of phosphatidylethanol counteracts the 
apparent phospholipase D-mediated formation in heart and other organs. Biochim. Biophys. Acta 
2003, 1633, 84–89. 
38. Moehren, G.; Gustavsson, L.; Hoek, J.B. Activation and desensitization of phospholipase D in 
intact rat hepatocytes. J. Biol. Chem. 1994, 269, 838–848. 
39. Pai, J.K.; Liebl, E.C.; Tettenborn, C.S.; Ikegwuonu, F.I.; Mueller, G.C.  
12-O-tetradecanoylphorbol-13-acetate activates the synthesis of phosphatidylethanol in animal 
cells exposed to ethanol. Carcinogenesis 1987, 8, 173–178. 
40. Aradottir, S.; Asanovska, G.; Gjerss, S.; Hansson, P.; Alling, C. PHosphatidylethanol (PEth) 
concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. 
Alcohol Alcohol. 2006, 41, 431–437. 
41. Hansson, P.; Caron, M.; Johnson, G.; Gustavsson, L.; Alling, C. Blood phosphatidylethanol as a 
marker of alcohol abuse: Levels in alcoholic males during withdrawal. Alcohol Clin. Exp. Res. 
1997, 21, 108–110. 
42. Hartmann, S.; Aradottir, S.; Graf, M.; Wiesbeck, G.; Lesch, O.; Ramskogler, K.; Wolfersdorf, M.; 
Alling, C.; Wurst, F.M. Phosphatidylethanol as a sensitive and specific biomarker: Comparison 
with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-deficient 
transferrin. Addict. Biol. 2007, 12, 81–84. 
43. Varga, A.; Hansson, P.; Lundqvist, C.; Alling, C. Phosphatidylethanol in blood as a marker of 
ethanol consumption in healthy volunteers: comparison with other markers. Alcohol. Clin. Exp. Res. 
1998, 22, 1832–1837. 
44. Wurst, F.M.; Alexson, S.; Wolfersdorf, M.; Bechtel, G.; Forster, S.; Alling, C.; Aradottir, S.; 
Jachau, K.; Huber, P.; Allen, J.P.; et al. Concentration of fatty acid ethyl esters in hair of 
alcoholics: Comparison to other biological state markers and self reported-ethanol intake.  
Alcohol Alcohol. 2004, 39, 33–38. 
45. Wurst, F.M.; Thon, N.; Aradottir, S.; Hartmann, S.; Wiesbeck, G.A.; Lesch, O.; Skala, K.; 
Wolfersdorf, M.; Weinmann, W.; Alling, C. Phosphatidylethanol: Normalization during 
detoxification, gender aspects and correlation with other biomarkers and self-reports. Addict. Biol. 
2010, 15, 88–95. 
46. Wurst, F.M.; Thon, N.; Weinmann, W.; Tippetts, S.; Marques, P.; Hahn, J.A.; Alling, C.; 
Aradottir, S.; Hartmann, S.; Lakshman, R. Characterization of sialic acid index of plasma 
apolipoprotein J and phosphatidylethanol during alcohol detoxification—A pilot study.  
Alcohol. Clin. Exp. Res. 2012, 36, 251–257. 
47. Varga, A.; Hansson, P.; Johnson, G.; Alling, C. Normalization rate and cellular localization of 
phosphatidylethanol in whole blood from chronic alcoholics. Clin. Chim. Acta 2000, 299, 141–150. 
48. Gnann, H.; Weinmann, W.; Thierauf, A. Formation of phosphatidylethanol and its subsequent 
elimination during an extensive drinking experiment over 5 days. Alcohol. Clin. Exp. Res. 2012, 
doi:10.1111/j.1530-0277.2012.01768.x. 
Int. J. Mol. Sci. 2012, 13 14810 
 
 
49. Bocckino, S.B.; Wilson, P.B.; Exton, J.H. Ca2+-mobilizing hormones elicit phosphatidylethanol 
accumulation via phospholipase D activation. FEBS Lett. 1987, 225, 201–204. 
50. Helander, A.; Zheng, Y. Molecular species of the alcohol biomarker phosphatidylethanol in 
human blood measured by LC-MS. Clin. Chem. 2009, 55, 1395–1405. 
51. Holbrook, P.G.; Pannell, L.K.; Murata, Y.; Daly, J.W. Molecular species analysis of a product of 
phospholipase D activation. Phosphatidylethanol is formed from phosphatidylcholine in phorbol 
ester- and bradykinin-stimulated PC12 cells. J. Biol. Chem. 1992, 267, 16834–16840. 
52. Morrill, G.A.; Ma, G.; Kostellow, A. Molecular species analysis of 1,2-diacylglycerol released in 
response to progesterone binding to the amphibian oocyte plasma membrane. Cell. Signal. 2000, 
12, 787–796. 
53. Huusko, T.J.; Liisanantti, M.K.; Nissinen, A.E.; Kakko, S.; Savolainen, E.R.; Vuoristo, J.T.; 
Savolainen, M.J. Effects of phosphatidylethanol on mouse adipocyte differentiation and 
expression of stearoyl-CoA desaturase 1. Alcohol. Clin. Exp. Res. 2007, 31, 376–382. 
54. Ikegwuonu, F.I.; Pai, J.K.; Mueller, G.C. Effects of steroids on the synthesis and metabolism of 
phosphatidylethanol in phorbol ester-activated lymphocytes. Carcinogenesis 1990, 11, 1927–1935. 
55. Gnann, H.; Engelmann, C.; Skopp, G.; Winkler, M.; Auwarter, V.; Dresen, S.; Ferreiros, N.; 
Wurst, F.M.; Weinmann, W. Identification of 48 homologues of phosphatidylethanol in blood by 
LC-ESI-MS/MS. Anal. Bioanal. Chem. 2010, 396, 2415–2423. 
56. Gnann, H.; Weinmann, W.; Engelmann, C.; Wurst, F.M.; Skopp, G.; Winkler, M.; Thierauf, A.; 
Auwarter, V.; Dresen, S.; Bouzas, N.F. Selective detection of phosphatidylethanol homologues in 
blood as biomarkers for alcohol consumption by LC-ESI-MS/MS. J. Mass Spectrom. 2009, 44, 
1293–1299. 
57. Nalesso, A.; Viel, G.; Cecchetto, G.; Mioni, D.; Pessa, G.; Favretto, D.; Ferrara, S.D. Quantitative 
profiling of phosphatidylethanol molecular species in human blood by liquid chromatography 
high resolution mass spectrometry. J. Chromatogr. A 2011, 1218, 8423–8431. 
58. Zheng, Y.; Beck, O.; Helander, A. Method development for routine liquid chromatography-mass 
spectrometry measurement of the alcohol biomarker phosphatidylethanol (PEth) in blood.  
Clin. Chim. Acta 2011, 412, 1428–1435. 
59. Sarri, E.; Servitja, J.M.; Picatoste, F.; Claro, E. Two phosphatidylethanol classes separated by thin 
layer chromatography are produced by phospholipase D in rat brain hippocampal slices.  
FEBS Lett. 1996, 393, 303–306. 
60. Gunnarsson, T.; Ekblad, L.; Karlsson, A.; Michelsen, P.; Odham, G.; Jergil, B. Separation of 
polyphosphoinositides using normal-phase high-performance liquid chromatography and 
evaporative light scattering detection or electrospray mass spectrometry. Anal. Biochem. 1997, 
254, 293–296. 
61. Gunnarsson, T.; Karlsson, A.; Hansson, P.; Johnson, G.; Alling, C.; Odham, G. Determination of 
phosphatidylethanol in blood from alcoholic males using high-performance liquid 
chromatography and evaporative light scattering or electrospray mass spectrometric detection.  
J. Chromatogr. B 1998, 705, 243–249. 
62. Varga, A.; Alling, C. Formation of phosphatidylethanol in vitro in red blood cells from healthy 
volunteers and chronic alcoholics. J. Lab. Clin. Med. 2002, 140, 79–83. 
Int. J. Mol. Sci. 2012, 13 14811 
 
 
63. Yon, C.; Han, J.S. Analysis of trimethylsilyl derivatization products of phosphatidylethanol by 
gas chromatography-mass spectrometry. Exp. Mol. Med. 2000, 32, 243–245. 
64. Varga, A.; Nilsson, S. Nonaqueous capillary electrophoresis for analysis of the ethanol 
consumption biomarker phosphatidylethanol. Electrophoresis 2008, 29, 1667–1671. 
65. Nalesso, A.; Viel, G.; Cecchetto, G.; Frison, G.; Ferrara, S.D. Analysis of the alcohol biomarker 
phosphatidylethanol by NACE with on-line ESI-MS. Electrophoresis 2010, 31, 1227–1233. 
66. Nissinen, A.E.; Makela, S.M.; Vuoristo, J.T.; Liisanantti, M.K.; Hannuksela, M.L.; Horkko, S.; 
Savolainen, M.J. Immunological detection of in vitro formed phosphatidylethanol—An alcohol 
biomarker—With monoclonal antibodies. Alcohol. Clin. Exp. Res. 2008, 32, 921–928. 
67. Nissinen, A.E.; Laitinen, L.M.; Kakko, S.; Helander, A.; Savolainen, M.J.; Horkko, S. Low 
plasma antibodies specific for phosphatidylethanol in alcohol abusers and patients with alcoholic 
pancreatitis. Addict. Biol. 2011, doi:10.1111/j.1369-1600.2010.00279.x. 
68. Tolonen, A.; Lehto, T.M.; Hannuksela, M.L.; Savolainen, M.J. A method for determination of 
phosphatidylethanol from high density lipoproteins by reversed-phase HPLC with TOF-MS 
detection. Anal. Biochem. 2005, 341, 83–88. 
69. Faller, A.; Richter, B.; Kluge, M.; Koenig, P.; Seitz, H.K.; Thierauf, A.; Gnann, H.; Winkler, M.; 
Mattern, R.; Skopp, G. LC-MS/MS analysis of phosphatidylethanol in dried blood spots versus 
conventional blood specimens. Anal. Bioanal. Chem. 2011, 401, 1163–1166. 
70. Marques, P.; Tippetts, S.; Allen, J.; Javors, M.; Alling, C.; Yegles, M.; Pragst, F.; Wurst, F. 
Estimating driver risk using alcohol biomarkers, interlock blood alcohol concentration tests and 
psychometric assessments: Initial descriptives. Addiction 2010, 105, 226–239. 
71. Marques, P.; Hansson, T.; Isaksson, A.; Walther, L.; Jones, J.; Lewis, D.; Jones, M. Detection of 
phosphatidylethanol (PEth) in the blood of drivers in an alcohol ignition interlock program. 
Traffic Inj. Prev. 2011, 12, 136–141. 
72. Stewart, S.H.; Reuben, A.; Brzezinski, W.A.; Koch, D.G.; Basile, J.; Randall, P.K.; Miller, P.M. 
Preliminary evaluation of phosphatidylethanol and alcohol consumption in patients with liver 
disease and hypertension. Alcohol Alcohol. 2009, 44, 464–467. 
73. Stewart, S.H.; Law, T.L.; Randall, P.K.; Newman, R. Phosphatidylethanol and alcohol 
consumption in reproductive age women. Alcohol. Clin. Exp. Res. 2010, 34, 488–492. 
74. Wurst, F.M.; Vogel, R.; Jachau, K.; Varga, A.; Alling, C.; Alt, A.; Skipper, G.E. Ethyl 
glucuronide discloses recent covert alcohol use not detected by standard testing in forensic 
psychiatric inpatients. Alcohol. Clin. Exp. Res. 2003, 27, 471–476. 
75. Comasco, E.; Nordquist, N.; Leppert, J.; Oreland, L.; Kronstrand, R.; Alling, C.; Nilsson, K.W. 
Adolescent alcohol consumption: biomarkers PEth and FAEE in relation to interview and 
questionnaire data. J. Stud. Alcohol. Drugs 2009, 70, 797–804. 
76. Hahn, J.A.; Dobkin, L.M.; Mayanja, B.; Emenyonu, N.I.; Kigozi, I.M.; Shiboski, S.;  
Bangsberg, D.R.; Gnann, H.; Weinmann, W.; Wurst, F.M. Phosphatidylethanol (PEth) as a 
Biomarker of Alcohol Consumption in HIV-Positive Patients in Sub-Saharan Africa.  
Alcohol. Clin. Exp. Res. 2012, 36, 854–862. 
Int. J. Mol. Sci. 2012, 13 14812 
 
 
77. Kip, M.J.; Spies, C.D.; Neumann, T.; Nachbar, Y.; Alling, C.; Aradottir, S.; Weinmann, W.; 
Wurst, F.M. The usefulness of direct ethanol metabolites in assessing alcohol intake in 
nonintoxicated male patients in an emergency room setting. Alcohol. Clin. Exp. Res. 2008, 32, 
1284–1291. 
78. Viel, G.; Boscolo-Berto, R.; Cecchi, R.; Bajanowski, T.; Vieira, N.D.; Ferrara, S.D.  
Bio-medicolegal scientific research in Europe. A country-based analysis. Int. J. Legal. Med. 2011, 
125, 717–725. 
79. Boscolo-Berto, R.; Viel, G.; Montagnese, S.; Raduazzo, D.I.; Ferrara, S.D.; Dauvilliers, Y. 
Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): A systematic review and  
meta-analysis of randomized controlled trials. Sleep Med. Rev. 2012, 16, 431–443. 
80. Boscolo-Berto, R. Clinical testing and evidence-based medicine: when the absence of evidence 
doesn’t mean evidence of absence. G. Ital. Nefrol. 2009, 26, 417. 
81. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. Control Clin. Trials 1986, 7, 177–188. 
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
